Literature DB >> 7058833

Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980.

D J Wallace, T E Podell, J M Weiner, M B Cox, J R Klinenberg, S Forouzesh, E L Dubois.   

Abstract

Nephritis developed in 230 of 609 private patients with systemic lupus erythematosus (SLE) (38 percent) followed up from 1950 to 1980. Eighty-seven percent of patients with nephritis were female; 71 percent were Caucasian. They were observed a mean of 10 years. Five- and 10-year survival rates were 80 percent and 65 percent, with improvement to 86 percent and 76 percent in the last decade. Normalization of urinary sediment and protein levels, blood pressure and serum albumin levels correlated with improved survival and tended to occur during the first year. Life-threatening complications of SLE were more common after the onset of nephritis but decreased as renal function worsened. Infection was the most frequent cause of death in the last decade. Forty-four patients received nitrogen mustard; 55 percent of the courses were followed by significant improvement in renal function and reduced steroid dosage. Control of the disease was associated with improved long-term survival of patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7058833     DOI: 10.1016/0002-9343(82)90812-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

1.  Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively.

Authors:  J C Nossent; W Bronsveld; A J Swaak
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  Relation between serological data at the time of biopsy and renal histology in lupus nephritis.

Authors:  J C Nossent; S C Henzen-Logmans; T M Vroom; V Huysen; J H Berden; A J Swaak
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

3.  Histopathological indicators of disease outcome in class IV lupus nephritis: a revisit of various indices.

Authors:  Manish Rathi; Krishan Lal Gupta; Kusum Joshi; Pramod K Gupta; Aman Sharma; Harbir Singh Kohli; Vivekanand Jha; Vinay Sakhuja
Journal:  Rheumatol Int       Date:  2015-03-11       Impact factor: 2.631

4.  Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States.

Authors:  Amy Devlin; Sushrut S Waikar; Daniel H Solomon; Bing Lu; Tamara Shaykevich; Graciela S Alarcón; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-12       Impact factor: 4.794

Review 5.  Systemic lupus erythematosus clinical issues.

Authors:  M B Stevens
Journal:  Springer Semin Immunopathol       Date:  1986

Review 6.  Prognosis in systemic lupus erythematosus.

Authors:  J M Esdaile
Journal:  Springer Semin Immunopathol       Date:  1994

Review 7.  Current treatment recommendations for lupus nephritis.

Authors:  C Ponticelli
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

8.  Immunosuppressive therapy modulates T lymphocyte gene expression in patients with systemic lupus erythematosus.

Authors:  Elayne Pereira; Márcia Cristina Tamia-Ferreira; Renato Sousa Cardoso; Stephano Spanó Mello; Elza Tiemi Sakamoto-Hojo; Geraldo A S Passos; Eduardo Antonio Donadi
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

9.  Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution.

Authors:  Paula I Burgos; Elizabeth L Perkins; Guillermo J Pons-Estel; Scott A Kendrick; Jigna M Liu; William T Kendrick; William J Cook; Bruce A Julian; Graciela S Alarcón; Clifton E Kew
Journal:  Arthritis Rheum       Date:  2009-09

10.  The actual survival rate in systemic lupus erythematosus: study of a 1976 cohort.

Authors:  M Breban; O Meyer; P Bourgeois; E Palazzo; M F Kahn
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.